Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Issue 8 (3rd July 2022)

• Record Type: Journal Article
• Authors: Chen, Evan C.; Liu, Yiwen; Harris, Courtney E.; Winer, Eric S.; Wadleigh, Martha; Lane, Andrew A.; Vedula, Rahul S.; Lindsley, R. Coleman; Copson, Kevin M.; Charles, Anne; Marty, Francisco; Neuberg, Donna; DeAngelo, Daniel J.; Stone, Richard M.; Luskin, Marlise R.; Issa, Nicolas C.; Garcia, Jacqueline S.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 8(2022)
• Page Start: 1934
• Page End: 1941
• Publication Date: 2022-07-03
• Subjects: Acute myeloid leukemia -- antifungal -- prophylaxis -- fungal infection; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2047964
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Antifungal prophylaxis (AFP) is recommended for acute myeloid leukemia (AML) patients receiving the combination of venetoclax (VEN) and a hypomethylating agent (HMA), but the benefit of this practice is unclear. We identified 131 patients with newly diagnosed AML who received frontline VEN/HMA and evaluated the use of AFP and its association with invasive fungal infections (IFIs) and AML outcomes. Seventeen percent of our patients received AFP at any time. Overall incidence of any IFI ('possible, ' 'probable, ' or 'proven' infection, as defined by the European Mycoses Study Group) was 13%, and the incidence did not differ based on AFP use ( p =.74). Median overall survival did not differ based on AFP use or lack thereof (8.1 vs. 12.5 months, respectively; p =.14). Our findings suggest that, at an institution where the incidence of fungal infections is low, there does not appear to be a role for AFP in newly diagnosed AML patients receiving VEN/HMA.